drugset / Trial / NCT05651672
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective single-arm phase II study to evaluate the efficacy and safety of Pemigatinib in the advanced gastrointestinal cancer with FGFR 1-3 alterations and failed standard therapy.
Timeline
- Start
- 2022-12-02
- Primary completion
- 2024-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemigatinib | Small molecule | 13.5 mg | Oral |